Surajit Das1, Hai-Shu Lin, Paul C Ho, Ka-Yun Ng. 1. Department of Pharmacy, Faculty of Science, National University of Singapore, Building S4, Rm 05-02, 18 Science Drive 4, Singapore 117543, Singapore.
Abstract
PURPOSE: This study aimed at the investigation of the impact of aqueous solubility and dose manipulation on the pharmacokinetics of resveratrol. METHODS: Water soluble intravenous and oral formulations of resveratrol were prepared with hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and randomly methylated-beta-cyclodextrin (RM-beta-CD), respectively. Sodium salt and suspension of resveratrol in carboxymethyl cellulose (CMC) were used as the reference intravenous and oral formulations, respectively. The pharmacokinetics of resveratrol was assessed in Sprague-Dawley rats. Plasma resveratrol concentrations were measured by high performance liquid chromatography (HPLC). RESULTS: Both HP-beta-CD and RM-beta-CD enhanced the aqueous solubility of resveratrol. After intravenous administration, rapid elimination of resveratrol was observed at all tested doses (5, 10, and 25 mg kg(-1)) regardless of formulation types; with non-linear elimination occurring at the dose of 25 mg kg(-1). RM-beta-CD significantly increased the maximal plasma concentration of orally administered resveratrol, but, it did not increase the oral bioavailability in comparison with the CMC suspension. Furthermore, the oral bioavailability remained unchanged among all tested doses (15, 25, and 50 mg kg(-1)). CONCLUSIONS: Aqueous solubility barrier might affect the speed but not the extent of resveratrol absorption. Further, dose manipulation (up to 50 mg kg(-1)) did not have a significant impact on the oral bioavailability of resveratrol.
PURPOSE: This study aimed at the investigation of the impact of aqueous solubility and dose manipulation on the pharmacokinetics of resveratrol. METHODS:Water soluble intravenous and oral formulations of resveratrol were prepared with hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and randomly methylated-beta-cyclodextrin (RM-beta-CD), respectively. Sodium salt and suspension of resveratrol in carboxymethyl cellulose (CMC) were used as the reference intravenous and oral formulations, respectively. The pharmacokinetics of resveratrol was assessed in Sprague-Dawley rats. Plasma resveratrol concentrations were measured by high performance liquid chromatography (HPLC). RESULTS: Both HP-beta-CD and RM-beta-CD enhanced the aqueous solubility of resveratrol. After intravenous administration, rapid elimination of resveratrol was observed at all tested doses (5, 10, and 25 mg kg(-1)) regardless of formulation types; with non-linear elimination occurring at the dose of 25 mg kg(-1). RM-beta-CD significantly increased the maximal plasma concentration of orally administered resveratrol, but, it did not increase the oral bioavailability in comparison with the CMC suspension. Furthermore, the oral bioavailability remained unchanged among all tested doses (15, 25, and 50 mg kg(-1)). CONCLUSIONS: Aqueous solubility barrier might affect the speed but not the extent of resveratrol absorption. Further, dose manipulation (up to 50 mg kg(-1)) did not have a significant impact on the oral bioavailability of resveratrol.
Authors: G Kuhnle; J P Spencer; G Chowrimootoo; H Schroeter; E S Debnam; S K Srai; C Rice-Evans; U Hahn Journal: Biochem Biophys Res Commun Date: 2000-05-27 Impact factor: 3.575
Authors: Alexandra Maier-Salamon; Birgit Hagenauer; Michael Wirth; Franz Gabor; Thomas Szekeres; Walter Jäger Journal: Pharm Res Date: 2006-08-09 Impact factor: 4.200
Authors: Chongwoo Yu; Young Geun Shin; Anita Chow; Yongmei Li; Jerome W Kosmeder; Yong Sup Lee; Wendy H Hirschelman; John M Pezzuto; Rajendra G Mehta; Richard B van Breemen Journal: Pharm Res Date: 2002-12 Impact factor: 4.200
Authors: Sandeep K Singh; Vishal Makadia; Shweta Sharma; Mamunur Rashid; Sudhir Shahi; Prabhat R Mishra; Mohammed Wahajuddin; Jiaur R Gayen Journal: Drug Deliv Transl Res Date: 2017-06 Impact factor: 4.617
Authors: Hai-Shu Lin; Vitaliy M Sviripa; David S Watt; Chunming Liu; Tian-Xiang Xiang; Bradley D Anderson; Pei Shi Ong; Paul C Ho Journal: J Pharm Biomed Anal Date: 2012-10-04 Impact factor: 3.935
Authors: Kinan Rahal; Phyllissa Schmiedlin-Ren; Jeremy Adler; Muhammad Dhanani; Victoria Sultani; Ahren C Rittershaus; Laura Reingold; Ji Zhu; Barbara J McKenna; Gregory M Christman; Ellen M Zimmermann Journal: Inflamm Bowel Dis Date: 2011-08-29 Impact factor: 5.325
Authors: Samuel Chao Ming Yeo; Peter S Fenwick; Peter J Barnes; Hai Shu Lin; Louise E Donnelly Journal: Br J Pharmacol Date: 2017-05-16 Impact factor: 8.739
Authors: Winyoo Chowanadisai; Kathryn A Bauerly; Eskouhie Tchaparian; Alice Wong; Gino A Cortopassi; Robert B Rucker Journal: J Biol Chem Date: 2009-10-27 Impact factor: 5.157